Works matching IS 11727047 AND DT 2019 AND VI 33 AND IP 1
Results: 8
Correction to: Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.
- Published in:
- 2019
- By:
- Publication type:
- corrected article
Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Impact of Antidepressant Use on the Trajectory of Alzheimer's Disease: Evidence, Mechanisms, and Therapeutic Implications.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Effects of Clozapine on the Gut: Cross-Sectional Study of Delayed Gastric Emptying and Small and Large Intestinal Dysmotility.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Opioidergic Agents as Antidepressants: Rationale and Promise.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
- Published in:
- 2019
- By:
- Publication type:
- journal article